Cargando…
The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study
BACKGROUND: Hyperuricemia is a risk factor for the onset of chronic kidney disease (CKD) and is significantly associated with the progression of CKD. However, there is no sufficient evidence by interventional research supporting a cause-effect relationship. Hyperuricemic patients without gouty arthr...
Autores principales: | Hosoya, Tatsuo, Kimura, Kenjiro, Itoh, Sadayoshi, Inaba, Masaaki, Uchida, Shunya, Tomino, Yasuhiko, Makino, Hirofumi, Matsuo, Seiichi, Yamamoto, Tetsuya, Ohno, Iwao, Shibagaki, Yugo, Iimuro, Satoshi, Imai, Naohiko, Kuwabara, Masanari, Hayakawa, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899617/ https://www.ncbi.nlm.nih.gov/pubmed/24433285 http://dx.doi.org/10.1186/1745-6215-15-26 |
Ejemplares similares
-
Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia
por: Gohda, Tomohito, et al.
Publicado: (2021) -
Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010) -
Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008) -
Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010) -
Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)